Key Takeaways BEAM and NTLA are compared as gene editing biotechs with pipelines at different development stages.BEAM advances multiple SCD programs and updates its BEAM-101 and BEAM-301 studies across phases.NTLA pushes late-stage in vivo candidates while a clinical hold on nex-z raises safety concerns.Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, NTLA i ...

Traders like heavily shorted stocks for two main reasons: either to bet on a decline in the company’s value, or to profit from a short squeeze.Here's a look at the top 10 most shorted stocks in the market right now. WEN stock is heavily shorted. See the details here. What Makes A Stock Heavily Shorted?The primary reason a stock becomes “heavily shorted” is that a large number of experienced traders and institutional investors—known as short sellers—believe the company is fundamentally overvalued and that it ...

Traders like heavily shorted stocks for two main reasons: either to bet on a decline in the company’s value, or to profit from a short squeeze.Here's a look at the top 10 most shorted stocks in the market right now. WEN stock is heavily shorted. See the details here. What Makes A Stock Heavily Shorted?The primary reason a stock becomes “heavily shorted” is that a large number of experienced traders and institutional investors—known as short sellers—believe the company is fundamentally overvalued and that it ...

Group 1 - Intellia Therapeutics, Inc. (NASDAQ:NTLA) is considered one of the most oversold biotech stocks, with a recent downgrade from Buy to Hold by Jones Trading following the announcement of a patient's death related to their treatment [1][2] - The downgrade was influenced by a key opinion leader call held by Dr. Garcia and Jones Trading to discuss the patient who met Hy's Law criteria, which occurred before the patient's death was announced [2] - Baird has lowered its price target for Intellia's shares to $9 while maintaining a Neutral rating, citing the FDA's hold on the NTLA-2001 treatment and the competitive landscape in the ATTR and HAE markets as significant challenges for commercial adoption [3] Group 2 - Intellia Therapeutics is at the forefront of CRISPR-Cas9 gene-editing technology, focusing on developing treatments for both in vivo and ex vivo applications, with its main initiative, NTLA-2001, targeting transthyretin amyloidosis, a currently incurable disease [4]

Key Takeaways Intellia stock plunged after the FDA placed a clinical hold on phase III studies of nex-z.The setback paused milestone guidance as Intellia works with regulators on next steps.NTLA eyes mid-2026 data for lonvo-z, which could become a key catalyst for the stock.Shares of Intellia Therapeutics (NTLA) have witnessed a sharp decline in the past month, primarily due to a regulatory setback faced with one of its lead in vivo candidates, nex-z (formerly known as NTLA-2001), as well as the mixed third ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price target to $8 from $17, citing uncertainty around the company’s ATTR program timeline. While acknowledging promising efficacy updates, the firm noted that clarity on development milestones remains lacking, narrowing the path to value. Evercore Downgrades Intellia (NTLA) Despi ...

Core Insights - Intellia Therapeutics is advancing two late-stage in vivo pipeline candidates: nex-z (NTLA-2001) for ATTR amyloidosis and lonvo-z (NTLA-2002) for hereditary angioedema (HAE) [1] Group 1: Nex-z Development - Intellia is collaborating with Regeneron Pharmaceuticals on nex-z, which is being evaluated in two late-stage studies: MAGNITUDE for ATTR amyloidosis with cardiomyopathy and MAGNITUDE-2 for ATTR amyloidosis with polyneuropathy [2] - Regeneron shares 25% of the development costs and commercial profits for nex-z, providing Intellia with additional resources for development [3] - The FDA placed a clinical hold on the MAGNITUDE studies due to observed Grade 4 liver enzyme elevations in under 1% of patients in the MAGNITUDE study, with none in MAGNITUDE-2 [4] - Intellia is working with investigators and regulators to address the clinical hold and has suspended its milestone guidance for nex-z until a regulatory path is established [5] Group 2: Lonvo-z Development - Intellia is also developing lonvo-z for HAE, with patient enrollment in the pivotal phase III HAELO study completed in September 2025, and top-line data expected by mid-2026 [6] - The regulatory setback for nex-z has raised concerns about the outlook for lonvo-z, making the HAE study outcome critical for Intellia's near-term success [7] Group 3: Competitive Landscape - Intellia's CRISPR-based therapies face competition from other companies utilizing CRISPR/Cas9 technology, which complicates the development process [8] - CRISPR Therapeutics is the first company to market a CRISPR/Cas9-based therapy, Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia [9] - Beam Therapeutics is also developing genome-editing candidates and in vivo therapies targeting various diseases [10][11] Group 4: Financial Performance - Year to date, Intellia's shares have declined by 25.6%, underperforming the industry, sector, and S&P 500 [13] - Intellia's shares are trading at a price/book ratio of 1.24, lower than the industry average of 3.65, and below its five-year mean of 3.01 [14] - The Zacks Consensus Estimate for Intellia's loss per share for 2025 has narrowed from $4.14 to $4.00, and for 2026 from $4.10 to $3.61 [15]

Core Viewpoint - Intellia Therapeutics faces significant challenges following a patient fatality in its clinical trial, leading to a regulatory hold and a sharp decline in stock value, raising concerns about the safety of its CRISPR technology and future prospects [3][4][20]. Company Overview - Intellia Therapeutics is a leader in CRISPR/Cas9 gene editing, focusing on next-generation therapies for disorders like hereditary angioedema and transthyretin amyloidosis, with a market capitalization of $1.1 billion [2]. - The company aims to transform gene editing into lasting, curative medicine through its scalable technology platform [2]. Recent Developments - NTLA stock has experienced volatility, dropping 66% from a peak of $28.25 in late October, with a 43% decline over the past year and a 19% year-to-date decrease [1]. - The stock's decline accelerated after Intellia paused dosing in its Phase 3 trials due to safety concerns, followed by an FDA-imposed clinical hold after a patient died from severe liver complications [3][4][6]. Financial Performance - In its third-quarter earnings report, Intellia reported revenues of $13.8 million, a 51% year-over-year increase, primarily due to cost reimbursements from a collaboration with Regeneron [9]. - Losses narrowed to $0.92 per share, better than expected, while R&D spending decreased by 23% to $94.7 million, indicating tighter cost control [10]. Analyst Sentiment - Following the recent setbacks, analysts have downgraded their price targets for NTLA stock, with Citizens JMP reducing its target to $21 from $29 while maintaining an "Outperform" rating [16]. - Truist Securities lowered its target to $14 from $25 but retained a "Buy" rating, emphasizing the potential for nex-z to move forward despite the recent tragedy [16]. - Overall, Wall Street's consensus rating for NTLA stock is "Moderate Buy," with a potential upside of 132% from current levels [19]. Future Outlook - Intellia has $669.9 million in cash and marketable securities, providing funding through mid-2027, allowing the company to regroup and refocus [13]. - The future of Intellia's other late-stage therapy, lonvoguran ziclumeran, remains uncertain, with pivotal data expected by mid-2026 [12]. - Analysts project a gradual narrowing of losses, with expectations of a 19% annual reduction this year and a further 10% improvement in 2026 [14].

Upgrades - JPMorgan upgraded Outfront Media (OUT) to Overweight from Neutral with a price target of $25, up from $19, citing the out-of-home channel as the most resilient traditional advertising market with improved momentum in Q3 [2] - Guggenheim upgraded Grail (GRAL) to Buy from Neutral with a price target of $100, noting that while Galleri is not a perfect test, it remains the leading commercially available MCED test with a significant data moat [3] - Piper Sandler upgraded Floor & Decor (FND) to Overweight from Neutral with a price target of $80, up from $75, highlighting potential for comparable sales improvement by Q1 of 2026 [4] - KeyBanc upgraded Progyny (PGNY) to Overweight from Sector Weight with a price target of $30, indicating limited share downside and several positive catalysts over the next 12 months [4] - KeyBanc upgraded AT&T (T) to Overweight from Sector Weight with a price target of $30, attributing the recent share pullback to overblown wireless competition concerns [5] Downgrades - Raymond James downgraded Bath & Body Works (BBWI) to Market Perform from Outperform, stating that the company's growth will be below its long-term potential due to slow improvements in digital capabilities and distribution [6] - Wolfe Research downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform, citing safety issues with nexiguran ziclumeran as a hindrance to the bull thesis [6] - Raymond James double downgraded Brighthouse Financial (BHF) to Market Perform from Strong Buy, referencing the announcement of its acquisition deal for $70 per share [6] - Raymond James double downgraded Centerspace (CSR) to Market Perform from Strong Buy, noting that while the portfolio is attractive for potential buyers, the recent rally has closed the valuation gap with multifamily peers [6] - Northland downgraded QuickLogic (QUIK) to Market Perform from Outperform, maintaining a price target of $5.95, after the company reported revenue in line with guidance and uncertainty regarding a $3M contract [6]

Group 1 - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment [1] - The article suggests that investors should consider the stock of SPSC, highlighting the opinions of analysts regarding its potential [1]